US 12,709,743 B2 · Compositions and methods for CRISPR/Cas-based gene editing

Abstract

The present invention relates to the field of nucleic acid editing, in particular to the field of clustered regularly interspaced short palindromic repeat (CRISPR) technology. Specifically, the present invention relates to Cas effector proteins, fusion proteins comprising such proteins, and nucleic acid molecules encoding them. The present invention also relates to complexes and compositions for nucleic acid editing (e.g., gene or genome editing), which comprise the proteins or fusion proteins of the present invention, or nucleic acid molecules encoding them. The present invention also relates to a method for nucleic acid editing (e.g., gene or genome editing), which uses the proteins or fusion proteins comprising the present invention.

Claims9

Dependent claims

A fusion protein, which comprises a first protein and a second protein or polypeptide;

wherein the first protein comprises or consists of a sequence as set forth in any one of SEQ ID NOs:
1, 2, and 3.

Dependencies are inferred from the claim text.

Facts

Application

18/990,889Filed 20 Dec 2024 · continuation

Priority

CN 202311130084.64 Sep 2023

Published

US 2025/0368974 A14 Dec 2025

Granted

18 Aug 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification22 codes

C12N 9/222
Ribonucleases [RNase]; Deoxyribonucleases [DNase]: clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
C12N 15/907
Using homologous recombination: in mammalian cells
C12N 9/22
Acting on ester bonds: ribonucleases [RNase]; Deoxyribonucleases [DNase]
C12N 15/102
Processes for the isolation, preparation or purification of DNA or RNA: mutagenizing nucleic acids

Compositions and methods for CRISPR/Cas-based gene editing

Life of this patent

Compositions and methods for CRISPR/Cas-based gene editing

Life of this patent

Abstract

Claims9